• OPEN AN ACCOUNT
Indian Indices
Sensex
78,499.17 -455.59
( -0.58%)
Global Indices
Nasdaq
54,056.75 150.65
(0.28%)
Dow Jones
7,778.11 47.15
(0.61%)
Hang Seng
65,597.55 -85.71
(-0.13%)
Nikkei 225
10,909.12 41.23
(0.38%)
Forex
USD-INR
95.20 0.13
(0.14%)
EUR-INR
109.83 0.08
(0.08%)
GBP-INR
128.13 0.14
(0.11%)
JPY-INR
0.60 0.00
(-0.12%)

EQUITY - MARKET SCREENER

Indrayani Biotech Ltd
Industry :  Diversified - Medium / Small
BSE Code
ISIN Demat
Book Value()
526445
INE007C01021
13.440188
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
79.27
68.07
EPS(TTM)
Face Value()
Div & Yield %
0.11
10
0
 

Wanbury explores new market opportunities for its new APIs
Jun 10,2026

Wanbury announced the company has expanded regulatory submission for launch of new Active Pharmaceuticals Ingredients (APIs).

For Diphenhydramine HCl, company submitted DMF to Malaysia and Singapore.

The Company proposed to explore new market opportunities for Paroxetine HCl in Korea and Latin America by submitting the DMFs.

Company also received formal audit report from MFDS (Korea FDA) for its Patalganga facility stating zero observation for the inspection conducted in April 2026.